Brief: Zai Lab And Novocure Announce Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant And Clinically Meaningful Extension In Overall Survival For Patients With Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
June 6 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB AND NOVOCURE ANNOUNCE LUNAR PHASE 3 CLINICAL TRIAL
DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL
EXTENSION IN OVERALL SURVIVAL FOR PATIENTS WITH METASTATIC
NON-SMALL CELL LUNG CANCER AFTER PLATINUM-BASED THERAPIES
* ZAI LAB LTD - TUMOR TREATING FIELDS THERAPY TOGETHER WITH
IMMUNE
CHECKPOINT INHIBITORS RESULTED IN 8-MONTH IMPROVEMENT IN MEDIAN
OVERALL SURVIVAL
Source text for Eikon: ID:nGNX8lmBLv
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows